The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Histone deacetylase 3 (HDAC3) is a potential target for the treatment of human diseases such as cancers, diabetes, chronic inflammation and neurodegenerative diseases. Previously, we proposed a virtual screening (VS) pipeline named “Hypo1_FRED_SAHA-3” for the discovery of HDAC3 inhibitors (HDAC3Is)...
Main Authors: | Jie Xia, Huabin Hu, Wenjie Xue, Xiang Simon Wang, Song Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2018.1437156 |
Similar Items
-
Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
by: Donya Naz Divsalar, et al.
Published: (2020-06-01) -
The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
by: Shalome A. Bassett, et al.
Published: (2014-10-01) -
A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing
by: Conrad V. Simoben, et al.
Published: (2018-03-01) -
Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening
by: Hui Lu, et al.
Published: (2011-12-01) -
The Role of HDACs as Leukemia Therapy Targets using HDI
by: Ahmad Ahmadzadeh, et al.
Published: (2016-02-01)